Clinical trial · Observational
Monitoring Neural Tissues Properties by Modulated Imaging (MI)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no subject
Summary
Brief summary (as posted)
We have developed a safe, non-contact, intra-operative guidance system to optimize tumor resection in neurosurgery. The Modulated Imaging is non-contact optical imaging technology developed at the Beckman Laser Institute, UCI. Compared to other imaging approaches, MI has the unique capability of performing both diffuse optical tomography and rapid, wide-field quantitative mapping of tissue optical properties within a single measurement platform. Preliminary in vivo studies have shown that brain tumors, infiltrating tumor margins and normal brain may have intrinsically different optical properties.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Modulated Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Modulated Imaging
- description
- Modulated Imaging
- interventionNames
- Device: Modulated Imaging
Primary outcomes (1)
- measure
- Brain Tissue Property
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Minute
Show eligibility criteria text
Inclusion Criteria: * All nervous system tumor patients who undergo a preoperative MRI,and undergoing central nervous system operative procedures for non tumor. Exclusion Criteria: * All emergency neurosurgical procedures.
References
Publications (0)
Data not yet available